Krystal Biotech KRYS 深 沪
已收盘 08-01 16:00:00 美东时间
156.98
+3.110
+2.02%
华盛通- 最 高159.00
- 今 开152.65
- 成交量 57.64万股
- 最 低 151.75
- 昨 收 153.87
- 总市值 45.37亿
- 52周最高 207.84
- 市盈率 静 52.36
- 换手率 0.00%
- 52周最低 122.80
- 委 比 -98.89%
- 总股本 2889.87万
- 历史最高 219.34
- 量 比 1.75
- 振 幅 4.71%
- 历史最低 8.03
- 每 手 1
- 风险率 33.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Outlook For Krystal Biotech
Krystal Biotech (NASDAQ:KRYS) is set to give its latest quarterly earnings repo...
08-02 03:01
Krystal Biotech to Report Second Quarter 2025 Financial Results on August 4, 2025
"PITTSBURGH, July 29, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ: KRYS), a commercial-stage biotechnology company, announced it will report its second quarter 2025 financial results on Monday, August 4, 2025, before the U.S. markets open. The Company’s management will host a conference call and webcast at 8:30 am ET on August 4 to discuss the financial results and provide a business update. Investors can access the live webcast at htt...
07-29 11:00
Krystal Biotech Gains Approval for DEB Treatment in Japan
An announcement from Krystal Biotech ( ($KRYS) ) is now available. On July 24, ...
07-25 21:29
Krystal Biotech Announces Approval of VYJUVEK® by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa
Krystal Biotech announced that Japan’s Ministry of Health, Labour and Welfare granted marketing authorization to VYJUVEK for the treatment of dystrophic epidermolysis bullosa (DEB) in patients from birth. VYJUVEK is the first genetic medicine approved in Japan for DEB, delivering functional copies of the COL7A1 gene to address the root cause of the disease. The drug can be administered at home or in a healthcare setting, with options for patients...
07-25 13:00
Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté
Jeune Aesthetics announced positive results from its Phase 1 PEARL-2 study of KB304, an investigational therapy for décolleté wrinkles. KB304 achieved statistically significant improvements in skin aesthetics, including wrinkle reduction, elasticity, and hydration, as measured by GAIS and SSQ. Ninety percent of subjects reported improved satisfaction with their skin's appearance. The treatment's safety profile was favorable, with mild-to-moderate...
07-24 12:00
美股大行评级 | 丰业银行上调Meta目标价从525美元升至675美元；恩智浦获"超配"评级，目标价从190美元升至220美元
今日重点评级关注：瑞杰金融：维持Antero Resources Corp."强烈买入"评级，目标价从57美元升至58美元；美银证券：维持和黄医药"买入"评级，目标价从27美元升至28美元
07-23 09:42
B of A Securities Maintains Buy on Krystal Biotech, Lowers Price Target to $192
B of A Securities analyst Alec Stranahan maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and lowers the price target from $193 to $192.
07-23 00:13
美股大行评级 | 巴克莱上调 Robinhood目标价至102美元；瑞银下调京东目标价从58美元至50美元
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从25美元升至29美元；摩根士丹利：维持Legend Biotech"超配"评级，目标价从80美元升至81美元
07-11 09:04
Citigroup Maintains Neutral on Krystal Biotech, Raises Price Target to $176
Citigroup analyst Carly Kenselaar maintains Krystal Biotech (NASDAQ:KRYS) with a Neutral and raises the price target from $155 to $176.
07-11 05:09
Krystal Biotech Has Dosed The First Patient In Its Phase 1/2 EMERALD-1 Trial Evaluating KB801 For Neurotrophic Keratitis
KB801 is a redosable eye drop gene therapy in development for the treatment of NK, a degenerative corneal disease characterized by damage or loss of function in the neurons innervating the eye leading to corneal
07-09 19:04
